C
Chunlin Zhao
Researcher at Hoffmann-La Roche
Publications - 7
Citations - 435
Chunlin Zhao is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Cancer & Cell cycle checkpoint. The author has an hindex of 4, co-authored 7 publications receiving 369 citations.
Papers
More filters
Journal ArticleDOI
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.
Binh Thanh Vu,Peter Michael Wovkulich,Giacomo Pizzolato,Allen John Lovey,Qingjie Ding,Nan Jiang,Jin-Jun Liu,Chunlin Zhao,Kelli Glenn,Yang Wen,Christian Tovar,Packman Kathryn E,Lyubomir T. Vassilev,Bradford Graves +13 more
TL;DR: RG7112 is the first clinical small-molecule MDM2 inhibitor designed to occupy the p53-binding pocket ofMDM2, which stabilizes p53 and activates the p 53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts.
Journal ArticleDOI
Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors.
Shaoqing Chen,Li Chen,Nam T. Le,Chunlin Zhao,Achyutharao Sidduri,Jian Ping Lou,Christophe Michoud,Louis Portland,Nicole Jackson,Jin-Jun Liu,Fred Konzelmann,Feng Chi,Christian Tovar,Qing Xiang,Yingsi Chen,Yang Wen,Lyubomir T. Vassilev +16 more
TL;DR: A novel series of quinolinyl-methylene-thiazolinones has been identified as potent and selective cyclin-dependent kinase 1 (CDK1) inhibitors, suggesting a potential use as antitumor agents.
Journal ArticleDOI
Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors
TL;DR: Synthesis of a focused pyrido-thieno-pyrimidine library yielded potent and selective Cdc7 inhibitors with antiproliferative activity against cancer cells in vitro.
Patent
Chiral cis-imidazolines
David Joseph Bartkovitz,Jianping Cai,Xin-Jie Chu,Hongju Li,Allen John Lovey,Binh Thanh Vu,Chunlin Zhao +6 more
TL;DR: In this paper, the authors provided compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein X, Y, Z, V1, V2, R 1, R 2, R 3, R 4 and R 5 are as described, processes for obtaining said compounds and pharmaceutical preparations containing them.
Patent
Novel Imidazolines as dual inhibitors of MDM2 and MDMX
TL;DR: In this paper, the compounds of Formula I or pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X23, X24, X25, X26, X27, X28, X30, X31, X32, X33,